HOPE Therapeutics, Inc., a wholly‑owned subsidiary of NRx Pharmaceuticals, Inc., announced today the acquisition of a strategic interest in Cohen & Associates, LLC, a premier interventional psychiatry clinic located in Sarasota, FL, and its incorporation into the HOPE network. Dr. Rebecca Cohen, MD, has been appointed as Medical Director, overseeing medical standards of care across HOPE’s Florida locations.
Cohen & Associates offers a full range of treatments for suicidal depression, PTSD, and other CNS disorders, including ketamine infusions, transcranial magnetic stimulation (TMS), and medication management. Dr. Cohen is an interventional psychiatrist and psychopharmacologist, nationally recognized as an expert in TMS, and founded her practice in 2014 as one of the first dedicated interventional psychiatry practices in the United States.
Strategically, the acquisition expands HOPE’s footprint in Florida, adding a high‑performing clinic to the network and enhancing the service portfolio available to patients. The appointment of Dr. Cohen brings specialized expertise and leadership that aligns with HOPE’s mission to deliver integrated, life‑transforming care for suicidal depression and related disorders.
The addition is expected to increase revenue, broaden patient access, and support NRx’s goal of generating near‑term profitability through the HOPE network. By integrating a proven clinic and a nationally recognized medical director, NRx strengthens its dual‑strategy model of drug development and direct patient care, positioning the company for accelerated growth and market penetration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.